Cardiovascular Prostheses

Abstract

Biomaterial compositions for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include a plurality of particulate structures. The biomaterial compositions include poly(glycerol sebacate) (PGS) and an antifibrotic. The biomaterial compositions can also include poly(glycerol sebacate) acrylate (PGSA) and an antifibrotic. The biomaterial compositions can further include acellular extracellular matrix (ECM) derived from a mammalian tissue source, such as small intestine submucosa, cardiac tissue and placental tissue. The biomaterial compositions are adapted to modulate inflammation of damaged tissue and induce neovascularization, host cell proliferation, remodeling of damaged tissue, and regeneration of new tissue and tissue structures.

What is claimed is: 
     
         1 . A biomaterial composition for treating damaged cardiovascular tissue, comprising:
 an ECM-mimicking composition comprising poly(glycerol sebacate) (PGS) and an antifibrotic,   said antifibrotic comprising paclitaxel,   said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising inflammation modulation of said damaged tissue and induced neovascularization, host cell proliferation, remodeling of the damaged tissue, and regeneration of new tissue and tissue structures.   
     
     
         2 . The composition of  claim 1 , wherein said ECM-mimicking composition further comprises poly(ε-caprolactone) (PCL). 
     
     
         3 . The composition of  claim 1 , wherein said ECM-mimicking composition further comprises a HMG-CoA reductase inhibitor. 
     
     
         4 . The composition of  claim 3 , wherein said HMG-CoA reductase inhibitor comprises cerivastatin. 
     
     
         5 . A biomaterial composition for treating damaged cardiovascular tissue, comprising:
 an ECM-mimicking composition comprising poly(glycerol sebacate) acrylate (PGSA) and an antifibrotic,   said antifibrotic comprising paclitaxel,   said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising inflammation modulation of said damaged tissue and induced neovascularization, host cell proliferation, remodeling of the damaged tissue, and regeneration of new tissue and tissue structures.   
     
     
         6 . The composition of  claim 5 , wherein said ECM-mimicking composition further comprises a HMG-CoA reductase inhibitor. 
     
     
         7 . The composition of  claim 6 , wherein said HMG-CoA reductase inhibitor comprises cerivastatin. 
     
     
         8 . A biomaterial composition for treating damaged cardiovascular tissue, comprising:
 an ECM/ECM-mimicking composition comprising acellular extracellular matrix (ECM) from a mammalian tissue source, poly(glycerol sebacate) (PGS) and an antifibrotic,   said antifibrotic comprising paclitaxel,   said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising inflammation modulation of said damaged tissue and induced neovascularization, host cell proliferation, remodeling of the damaged tissue, and regeneration of new tissue and tissue structures.   
     
     
         9 . The composition of  claim 8 , wherein said mammalian tissue source is selected from the group consisting of small intestine submucosa, stomach submucosa, urinary bladder submucosa, cardiac tissue, placental tissue, mesothelial tissue and omentum tissue. 
     
     
         10 . The composition of  claim 8 , wherein said ECM-mimicking composition further comprises a HMG-CoA reductase inhibitor. 
     
     
         11 . The composition of  claim 10 , wherein said HMG-CoA reductase inhibitor comprises cerivastatin.